Lung cancer surgery in oligometastatic patients: outcome and survival.
暂无分享,去创建一个
F. Petrella | M. Casiraghi | D. Galetta | Juliana Guarize | L. Spaggiari | F. de Marinis | P. Maisonneuve | L. Bertolaccini | G. Sedda | J. Guarize
[1] L. Spaggiari,et al. The radical approach to the oligometastatic not small cell lung cancer patient: which? how? when? where? , 2019, Journal of thoracic disease.
[2] A. Gavin,et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.
[3] R. Crisci,et al. Surgical approach in the oligometastatic patient. , 2018, Annals of translational medicine.
[4] P. V. Van Schil,et al. Oligometastatic non-small cell lung cancer: is there a role for locoregional therapy? , 2017, Journal of thoracic disease.
[5] R. Rengan,et al. Oligometastatic non-small-cell lung cancer: current treatment strategies , 2016, Lung Cancer.
[6] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[7] Henry Knipe,et al. Oligometastases , 2016, Radiopaedia.org.
[8] G. Varela,et al. Surgical management of oligometastatic non-small cell lung cancer. , 2016, Journal of thoracic disease.
[9] David R. Jones,et al. Management of stage IIIA (N2) non-small cell lung cancer: A transatlantic perspective. , 2016, The Journal of thoracic and cardiovascular surgery.
[10] J. Crowley,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] Hiroko Watanabe,et al. Characteristics of clinical N0 metastatic non-small cell lung cancer. , 2015, Lung cancer.
[12] L. Konge,et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[13] L. Konge,et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) , 2015, Endoscopy.
[14] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[15] Douglas G Altman,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.
[16] Umberto Ricardi,et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. , 2014, Clinical lung cancer.
[17] G. Rodrigues,et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. , 2013, Lung cancer.
[18] B. Yaremko,et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. , 2013, Lung cancer.
[19] C. Gridelli,et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Stahel,et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. , 2012, Lung cancer.
[21] G. Apolone,et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. , 2012, The Journal of thoracic and cardiovascular surgery.
[22] Jeffrey W. Clark,et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.
[23] F. Cappuzzo,et al. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. , 2010, The oncologist.
[24] J. Crowley,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] N. Demartines,et al. Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.